Unknown

Dataset Information

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study.


ABSTRACT:

Background

Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients who may benefit from palbociclib treatment.

Methods

We retrospectively analyzed the values of Ki67 and progesterone receptor (PR) as detected by immunohistochemistry in 81 ABC patients with palbociclib and hormone therapy treatment, and evaluated the impact on progression-free survival (PFS).

Results

In the total population, women with Ki67 ≥14% had marginally significantly shorter PFS than those with Ki67 <14% (P=0.062). Patients with Ki67 ≥30% had significantly shorter PFS t

SUBMITTER: Shao X 

PROVIDER: S-EPMC8106007 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature